News / Publication

Chugai and Biomy Enter into Memorandum of Understanding for Joint Development of AI-Based Cancer Pathology Diagnostic Support Program

By developing a support program for evaluating neoadjuvant therapy effectiveness, Chugai and Biomy aim to improve pathology diagnosis throughput and standardize pathologic response assessment, contributing to optimal treatment selection for patients By developing a program that detects features related to prognosis and drug efficacy from the tumor microenvironment, the two companies aim to realize personalized healthcare and maximize the value of pharmaceuticals TOKYO, No

2 時間前

Present Abstracts at the 2025 ASCO Annual Meeting

Biomy announced the presentation of abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago,...

5月29日

NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field

Tokyo, Japan, January 10, 2025  – NEC Corporation (NEC; TSE: 6701) and Biomy, Inc. (Biomy) have signed a Memorandum of Understanding...

1月10日

New round financing completed

Biomy, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Teppei Konishi; hereinafter referred to as "our company"), which boasts advanced...

2024年8月20日